Berberine as a Potential Agent for the Treatment of Colorectal Cancer

Frontiers in Medicine

article

Xi Jiang¹  Zhongxiu Jiang²  Min Jiang³  Yan Sun⁴ 

[1] Department of Cardiology, Shengjing Hospital of China Medical University;Department of Oncology, Shengjing Hospital of China Medical University;Department of Gastroenterology, First Affiliated Hospital of China Medical University;Department of Gastroenterology, Shengjing Hospital of China Medical University

关键词: berberine;    colorectal cancer;    antitumor;    gut microbiota;    mucosal barrier;   

DOI  :  10.3389/fmed.2022.886996

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Colorectal cancer (CRC) is one of the most commonly diagnosed and deadly malignancies worldwide. The incidence of CRC has been increasing, especially in young people. Although great advances have been made in managing CRC, the prognosis is unfavorable. Numerous studies have shown that berberine (BBR) is a safe and effective agent presenting significant antitumor effects. Nevertheless, the detailed underlying mechanism in treating CRC remains indistinct. In this review, we herein offer beneficial evidence for the utilization of BBR in the management and treatment of CRC, and describe the underlying mechanism(s). The review emphasizes several therapeutic effects of BBR and confirms that BBR could suppress CRC by modulating gene expression, the cell cycle, the inflammatory response, oxidative stress, and several signaling pathways. In addition, BBR also displays antitumor effects in CRC by regulating the gut microbiota and mucosal barrier function. This review emphasizes BBR as a potentially effective and safe drug for CRC therapy.

【 授权许可】

CC BY